Preclinical Capabilities

Optimal Study Design to Advance Your Therapeutic Program

TD2 is your trusted, experienced team when it comes to running preclinical oncology studies. Our extensive knowledge in both solid and hematologic tumors, immuno-oncology and adoptive cell therapy enables optimal study design and rapid study initiation.

Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Our team has been involved in 600+ first in human studies. We have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.

Comprehensive preclinical services.

Personalized, Expert Support

  • 300+ established mouse models
    • Syngeneic
    • Adoptive cell therapy models
    • VK*Myc mouse
    • Glioblastoma PDX
    • Humanized mouse models
    • Orthotopic
  • 400+ cancer cell lines
    • Well-characterized
    • Precision dosing – Tecan D300 digital dispenser
    • Combination interactions with immune effector cells
    • Synergy studies
  • Non-GLP safety and tolerability
  • Bioanalytical and DMPK capabilities
  • Biomarker screening
  • Optical imaging

Learn more about our Preclinical services.

Contact our experts to help advance your cancer therapeutic with our trusted preclinical research services.

Optimal Study Design to Advance Your Therapeutic Program

Syngeneic mouse models Syngeneic tumor models are fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors.

One Consistent Host — through 16S ribosomal RNA (rRNA) gene sequencing launched before the study even begins, we define the microbiome at the onset, which enables your project focused access to a known and stable host from start to finish.

Find Effector Cells — through multi-parameter flow cytometry, we can characterize phenotypic immune cell population changes post-treatment. See available models

CAR-T capabilities

Having performed more than 100 studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your adoptive cell therapy program.

TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability.  See available cell lines

Humanized mice

• Human PBMCs or effector cell engraftment
• Sourced CD34+ humanized mice

Get Started

Work with a team who believes in your research as much as you do.

Are you ready to start your preclinical studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.

Get Started Now

Cancer Type Syngeneic Line Expression Data Available
PD-1 PD-L1 PD-L2 CTLA4 Other
Bladder MB-49
MBT-2		         
Brain GL261        
Breast 4T1
4T1-Luc
EMT-6
EO771		               
Colon Colon 26-Luc
colon 26
CT-26
MC-38		                    TIM-3, OX40
CD40
Hematologic EL-4 (Lymphoma)
MPC-11 (Myeloma)		 Growth Kinetics
Growth Kinetics
Hepatoma Hepa 1-6      
Lung KLN205
LL/2
LL/2-Luc
TC-1 (HPV-Associated)		                   Growth Kinetics
Ovarian ID8-Luc Growth Kinetics
Mastocytoma P815 Growth Kinetics
Pancreas Pan02
Pan02 (Orthotopic)		        TIM-3, GITR
Renal RENCA      
Sarcoma K7M2 (IV) Growth Kinetics
Skin B16-F1
B16-F10
B16-BL6		                
786-0 Human Renal Cell Carcinoma KKU-M213 human intrahepatic cholangiocarcinoma
A2780: Human Ovarian MCF-7 Human Breast
A498: Human Renal Cell Carcinoma MM1.s Human Multiple Myeloma
ACHN Renal Cell Adenocarcinoma Nalm6-Fluc-GFP Acute Lymphoblastic Leukemia
BxPC3 Human Pancreas Nalm-6 Human Acute Lymphoblastic Leukemia
Caki-1 Human Renal Cell Carcinoma NCI-H660 Human Prostate Neuroendocrine
Caki-2 Human Renal Cell Carcinoma NCI-H1963 Human Lung
CCRF-CEM Human Acute T Cell Lymphoblastic Leukemia NCI-H1975 Human Non-Small Cell Lung
H69 Human Small Cell Lung NCI-N87 Human Gastric
H209 Human Lung OV90 Human Ovarian
HCC70 Human Breast OVCAR-3 Human Ovarian
HCC1954 Human Breast Raji Human Burkett’s Lymphoma
HCT116 Human Colon RPMI-8226 Human Myeloma
HH Human Cutaneous T Cell Lymphoma SKOV-3 Human Ovarian
Hs766T Human Pancreas SNU-1 Human Gastric Carcinoma
HT-55 Human Colorectal SW-480 Human Colon
HuT78 Human Cutaneous T Lymphocyte SW-620 Human Colon
Jeko-1 Human Mantle Cell Lymphoma THP-1 Human Acute Myeloid Leukemia
Jurkat-Luc Human Acute T Cell Leukemia Toledo Human Diffuse Large B-Cell Lymphoma
Skip to content